{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-074374","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2025-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.503131+00:00","generated_at":"2026-05-21T01:10:13.819482+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Plus Therapeutics receives Nasdaq delisting notice for bid price below $1.00","bullets":["Nasdaq notified Plus Therapeutics on May 16, 2025 of non-compliance with minimum bid price rule (closing bid < $1.00 for 30 consecutive days).","Initial compliance period ends November 12, 2025; must close at $1.00+ for 10 consecutive business days.","If not cured by Nov 12, may be eligible for additional 180-day period if meets other listing standards.","Company will consider options including reverse stock split to regain compliance; no assurance of success.","Potential delisting can be appealed; common stock continues trading on Nasdaq during process."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-074374","json":"https://secwatch.observer/filing/0000950170-25-074374.json","markdown":"https://secwatch.observer/filing/0000950170-25-074374.md","text":"https://secwatch.observer/filing/0000950170-25-074374.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000095017025074374/0000950170-25-074374-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000095017025074374/pstv-20250516.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T01:10:13.819482+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ae784d6f2b50ce0b249d9b354f0b10d99c8fa1c","claim":"PLUS THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"May 16, 2025, Plus Therapeutics, Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). Nasdaq’s notice has no immediate effect on the listing or trading of the Company’s common stock. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided an initial compliance period of 180 ca","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1095981/000095017025074374/0000950170-25-074374-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}